Latest news and press releases about OmniAb, Inc. (OABI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments.
Price
| Price | $4.35 |
| Market Cap | $631M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.15 |
| EV / EBITDA | -24.44 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -16.59% |
| Return on Invested Capital | -17.24% |
| Return on Assets | -15.25% |
| Gross Margin | 50.53% |
| Operating Margin | -125.79% |
| Net Margin | -115.18% |
Related companies: ARMP · CCCC · CDXS · IMDX · IPHA · IVVD · MIST
Explore sector: Healthcare · Biotechnology
More sections of OABI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks